Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2021 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...
July 29, 2021 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Report Second Quarter 2021 Financial Results on August 5

BOSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
July 20, 2021 17:21 ET | Source: Albireo Pharma, Inc.

MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority...
July 20, 2021 16:00 ET | Source: Albireo Pharma, Inc.

Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority...
July 19, 2021 08:01 ET | Source: Albireo Pharma, Inc.

Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)

– First approval in the world of Bylvay for the treatment of PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – European Commission (EC) decision based on data from the largest...
July 08, 2021 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Present at the William Blair Biotech Focus Conference 2021

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...
June 24, 2021 08:00 ET | Source: Albireo Pharma, Inc.

Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...
June 21, 2021 06:00 ET | Source: Albireo Pharma, Inc.

Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress

– Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters – – Bylvay patient responder data show sustained improvements in...
June 10, 2021 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Showcase New Data at the EASL International Liver Congress™ 2021

– Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay™ (odevixibat) – – Data presentations on Phase 1 product candidate, A3907, in development for adult...
June 03, 2021 16:30 ET | Source: Albireo Pharma, Inc.

New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC

– Data being presented show long-term benefits of Bylvay in children with PFIC – – First potential non-invasive treatment option that could transform the treatment paradigm – – Observed long-term...